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11. Epidemiology 
~ Gender differences in the Scandinavian CF population 
H.V Olesen, T. Pressler, L. Hjelte, L. Mared, M. Johannesson. Scandinavian 
CF Study Consortium 
Aims: Poorer survival, earlier acquisition of Pseudomonas eruginosa (Ra.) and 
higher prevalence of diabetes mellitus (DM) for female CF patients have been 
reported. The aim of this study was to see if this was also true for CF females in 
Scandinavia. 
Methods: Data from the Scandinavian Pseudomonas Prevalence Study were anal- 
ysed for gender differences. 898 (420 F/478 M) pancreatic nsufficient patients were 
included. 
Inclusion data: age, BMI, lung function, bacterial colonisation, DM. Chronic Ra. 
infection was defined as serum precipitins of ~> 2 at inclusion and end of study 
(14 months). Days of intravenous antibiotics and hospitalisation were recorded. 
Results: 195 females (46%) and 195 (40%) males had a chronic Ra. infection 
(p 0.089). Females had higher prevalence in all 5-year age-groups, though only 
significantly in the 30+ group (p 0.031). 16 females (4%) and 9 males (2°/0) 
had Burkh. infection (p 0.067). Adult women had a median of 39 days on i.v. 
antibiotics/year versus 26 days for men (p 0.01), and spent more days in hospital 
(mean 20 versus 13; p 0.01). No difference was seen in lung function and BMI. 
60 females (14°/0) had DM versus 59 males (12°/0), p 0.43. 12 females (3°/0) and 6 
males (1°/0) died or were lung transplanted during the study (p 0.087). Mean age 
of death/lung transplantation was 27y for females and 22y for males (p 0.26). 
Significantly more adult males (56°/0) than females (44°/0) implied difference in 
mortality. 
Conclusions: A trend was seen towards a higher prevalence of chronic Ra. 
infections in females as well as more days of i.,~ antibiotics and hospitalisation. 
Since the adult group had more males than females, the lack of differences in 
lung function, BMI and diabetes might be due to an excess mortality in the female 
patients, hinted in the doubled rate of death/lung transplantation among the women. 
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l~The  Cystic Fibrosis Siblings Study 
M. Riddle 1 , K. Giles 2, S. Cottrell 1 , J. Maddison 1 , G. Connett 1 . lRegional CF 
Service, Southampton General Hospital, 2The South and West CF database, Bath, 
UK 
Parents of CF children face difficult decisions concerning future pregnancies. For 
some, antenatal diagnosis and termination of a second CF child is undesirable. This 
study was designed to determine whether having siblings with CF adversely affects 
clinical outcome. We hypothesised that those with CF siblings do less well because 
of factors such as cross infection. 
Method: The South and West CF Database was used to identify the following; 
those with no CF affected sibling, those with one or more affected CF siblings 
(including CF twins). A dataset from 1990 to 2004 was analysed, thus providing 
a series of cross-sectional nalyses. Outcome measures were compared using t and 
Mann-Whitney U tests where appropriate. 
Results: Three cohorts were analysed; 284 children aged 7 years (232 without 
CF siblings, 52 with CF siblings, 14 twins), 299 aged 10 years (241 without 
CF siblings, 58 with CF siblings, 14 twins), 270 aged 15 years (200 without 
CF siblings, 70 with CF siblings, 5 twins). In all cohorts there was a significant 
difference for growth of Pseudomonas in the last year, (with CF sibling 86/175 vs 
without CF sibling 332/673, p<0.01, CF twins 21/33 vs without CF sibling 
332/673, p < 0.01). There was no significant difference for other outcome measures 
at any age and after analysing outcomes for siblings separately. (FEV1 87% vs 
85%, banding score 2.16 vs 2.2, BMI SDS 0.07 vs 0.04 for aggregated data). 
Conclusion: Despite differences in Pseudomonas colonisation there were no dif- 
ferences in clinically relevant outcomes indicating more severe disease. These 
data provide useful information for parents of CF children considering future 
pregnancies. In this study we found no evidence that children with CF are adversely 
affected when there are two or more siblings in the same family. 
1461"1 Is CF more severe in females (F) than in males (M)? - Survival 
analysis from the Italian Cystic Fibrosis Registry (ICFR) 
L. Viviani 1 , A. Bossi 1 , B.M. Assael 2 & Italian CF Centres Directors*. 1Institute 
of Medical Statistics and Biometry, Milan, 2 Verona CF Centre, Italy 
According to some, but not all, epidemiological studies, CF is more severe and 
causes earlier mortality in females (F) than in males (M). 
Methods: the Italian Cystic Fibrosis Registry (ICFR) was implemented in 1988 and 
30 CF Italian centres prospectively collected ata of patients alive on Jan 1 st, 1988 
and of all those diagnosed thereafter (n 5191). We performed survival analysis on 
5175 subjects (F 2522) according to gender, period and mode of diagnosis. 
Results: 717 deaths were related to CF (F 385, M 332; p < 0.009). Kapla~Meier 
survival curves were highly different between F and M (Log-rank p < 0.0006). 
Survival probability at age 18 years was 90% for F and 92% for M. The data 
were period dependent: M and F born ~>1988 (M 1183, F 1170; 78 deaths) had 
not significantly different survival, either those diagnosed by neonatal screening 
(n 512) or by symptoms (n 928). Moreover, while numbers of F and M are 
equal for patients born ~> 1988, the proportion of M was higher among those born 
<1988. This could be a selection bias due to higher precocious mortality of E A 
similar number of F and M underwent lung transplantation. 
Conclusions: taken together, these data indicate that earlier death in F should no 
longer be seen in the more recent cohorts of patients. Analysis of lung function 
data in the registry is ongoing to determine whether or not lung disease is more 
severe in F although not causing earlier mortality. 
*Italian CF Centres Directors: Barlocco E, Bignamini E, Carnovale V, Colombo C, 
Cosimi A, De Rose V, Gagliardini R, Grzincich G, La Rosa M, Lucidi V, 
Magazzfi G, Manca A, Miano A, Minicucci L, Monti A, Moretti R Negri A, 
Padoan R, Pardo F, Poli F, Provenzano E, Quattrucci S, Raia V, Ratclif L, Repetto T, 
Salvatore D, Zanda M. 
1• Improved survival in Cystic Fibrosis associated with the 
specialized center care 
S. Fustik, T. Jakovska, L. Spirevska, B. Pecevska. Pediatric Clinic, Clinical Cenlre, 
Skopje, Republic of Macedonia 
To improve the survival and quality of life of cystic fibrosis (CF) patients in Republic 
of Macedonia, the program for development of specialized CF center at the Pediatric 
Clinic in Skopje was established in 1996/97. 
The aim of the study was to evaluate the results of the new therapeutic approaches 
and management of CF patients, by analyzing of the demographic data (age, gender, 
age of death if applicable) and the cumulative survival of CF patients treated at our 
clinic over two periods: from 1989 to the end of 1996, and from 1997 to the end 
of 2004. 
The First 8 years, 63 CF patients (37 males, 26 females) were treated. A great 
number of those patients (28 or 44.4%) died during that period, most of them (21 
or 75%) in infancy. The mean age of death was 1.83±2.73 years. The mean age 
of survived patient at the end of the firs study period was 6.48±3.81 years. The 
second 8 years, 94 CF patients (57 males, 37 females) have attended the CF centre. 
During that period 6 (6.38%) deaths occurred, 2 (33.3%) of them in young infant 
age. The mean age of death was 4.04±4.11 years. The mean age of alive patients 
at the end of the second period was 9.55±6.14 years and they were significantly 
older than the patients in the first period. CF population in Macedonia is getting 
larger and older. The proportion of the patients older than 12 years (13 years and 
more) at the end of 2004 was 32.9% in comparison with only 5.7%, at the end of 
1996. The estimation of cumulative survival in the two analyzed periods showed 
significantly higher cumulative survival in the second period (0.908) compared to 
first period (0.455). 
In conclusion, the lifetime provision of medical care within a specialized CF centre 
is associated with considerable decrease of mortality rate and improved survival of 
CF patients. 
